CRISPR PCSK9 Gene Editing (Verve-101)

Type: gene_editing

Status: Investigational

Developer: Verve Therapeutics

Breakthrough Summary

No summary available.

Mechanism of Action

One-time base editing to permanently lower LDL

Year: 2024-2026